NNNN
Anbio Biotechnology Class A Ordinary SharesNNNN
NNNN
About: Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. Its research and development activities for all IVD products: Biomarker Discovery and Validation, Assay Development, Validation - Clinical and Analytical and Platform Transfer. Its product AF-1200 Fluorescence Immunoassay Analyzer, AF-100 Fluorescence Immunoassay Analyzer, AF-100S Fluorescence Immunoassay Analyzer, AF-100C Fluorescence Immunoassay Analyzer.
–
Funds holding %
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for NNNN.
Financial journalist opinion
Based on 3 articles about NNNN published over the past 30 days
Neutral
Seeking Alpha
15 hours ago
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings
The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahead, although some small deals may list throughout it.
Neutral
GlobeNewsWire
2 days ago
Anbio Biotechnology Announces Closing of Initial Public Offering
Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares began trading on the Nasdaq Global Market on February 19, 2025 under the ticker symbol “NNNN.”
Neutral
GlobeNewsWire
3 days ago
Anbio Biotechnology Announces Pricing of Initial Public Offering
Frankfurt am Main, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the pricing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (“the Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on February 19, 2025 under the ticker symbol “NNNN.”
Neutral
Seeking Alpha
1 month ago
U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings
Two small IPOs listed this week - INLIF and OneConstruction Group. Five issuers and two SPACs submitted initial filings this week. The 2025 IPO market is here, and while there are a few small deals on the calendar, some large names in the pipeline could launch in the week ahead.
Neutral
Seeking Alpha
1 month ago
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch
Anbio Biotechnology plans to raise $8.8 million in an IPO to commercialize its in vitro diagnostics products amid market risks. The company has experienced fluctuating revenue and profitability, with significant customer concentration risks. The global IVD market is projected to grow to $119 billion by 2030, but Anbio faces stiff competition from well-established industry players.
Charts implemented using Lightweight Charts™